Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Vaccine Trial
100%
Tumor
100%
Tumor Immunity
100%
Prostate Cancer
100%
Paraneoplastic Syndrome
100%
Vaccination
66%
Immunogenicity
66%
Prostate Tumor Cells
66%
Autologous Dendritic Cells
66%
Dendritic Cell Vaccine
66%
Clinical Trials
33%
CD4+
33%
Fold Increase
33%
Immunogenic Tumor
33%
Prostate-specific Antigen
33%
Placebo-controlled Study
33%
T Cell Proliferation
33%
Allogeneic
33%
Immunogenic
33%
Delayed Hypersensitivity
33%
Therapeutic Vaccine
33%
Prostate Cancer Patients
33%
Prostate-specific Antigen Doubling Time
33%
Proliferation Response
33%
Foxp3+ Regulatory T Cells
33%
Cancer Cell Vaccine
33%
Tumor Immune Response
33%
CD8+ T Cell Infiltration
33%
Medicine and Dentistry
Neoplasm
100%
Prostate Cancer
100%
Tumor Immunity
100%
Neurologic Disease
75%
Prostate Tumor
50%
Prostate Specific Antigen
50%
Tumor Cell
50%
Dendritic Cell Vaccine
50%
Immunogenicity
50%
T Cell Proliferation
50%
Clinical Trial
25%
T-Helper Cell
25%
In Vitro
25%
Cancer Cell
25%
Immune Response
25%
Cytotoxic T-Cell
25%
Hypersensitivity Response
25%
Regulatory T Cell
25%
Placebo-Controlled Study
25%
Delayed Hypersensitivity
25%
Tumor Vaccine
25%
Cell Vaccine
25%
Immunology and Microbiology
Prostate
100%
Tumor Immunity
100%
Tumor Cell
66%
T Cell Proliferation
66%
Immunogenicity
66%
Prostate Specific Antigen
66%
Dendritic Cell Vaccine
66%
T-Helper Cell
33%
Cancer Cell
33%
Cytotoxic T-Cell
33%
Immune Response
33%
Regulatory T Cell
33%
Delayed Hypersensitivity
33%
Tumor Vaccine
33%
In Vitro
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Prostate Cancer
100%
Neurologic Disease
42%
Prostate Tumor
28%
Prostate Specific Antigen
28%
Immunogenicity
28%
Dendritic Cell Vaccine
28%
Malignant Neoplasm
14%
Clinical Trial
14%
Placebo-Controlled Study
14%
CD8 Antigen
14%
Delayed Hypersensitivity
14%
Tumor Vaccine
14%
Cell Vaccine
14%